Cognitive improvements observed with second-generation antipsychotics in older schizophrenia patients are likely true effects rather than retesting artifacts.
Supports genuine cognitive benefits of second-generation antipsychotics in older schizophrenia patients; leaves open confirmation via randomized trials.
The data suggest that the findings of modest cognitive improvements seen in some prior studies of schizophrenia patients when treated with second-generation antipsychotic medications were probably not due to simple retesting artifacts. At the same time, because of the variance in some of these test-retest performances, relatively substantial changes in performance on the part of individual patients would be required to be clearly interpretable.
No takes yet. Share an insight, caveat, or question.
Harvey et al. (2004) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: